Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Teva Pharmaceutical Industries Limited Ordinary Shares
(NY:
TEVA
)
39.21
+0.67 (+1.74%)
Delayed Quote
Updated: 12:10 PM EST, Nov 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Teva Pharmaceutical Industries Limited Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Teva Announces R&D Leadership Transition; Eric Hughes to Depart the Company
November 18, 2026
Teva's Pivot to Growth Strategy, R&D priorities, and expectations remain unchanged; Company initiates search for successor
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
U.S. FDA Approves IGALMI® as First At-Home Acute Treatment for Agitation Associated with Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder in Adults
November 16, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030
November 11, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion
November 03, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.
November 03, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-‘286) Following Interim Futility Analysis
November 02, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
October 27, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease
October 20, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva to Host R&D Day on Wednesday, November 11 in New York City
October 12, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia
October 09, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome
October 02, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients
October 02, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness
September 30, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
September 28, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Releases Q3 2026 Aide Memoire
September 23, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
September 23, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
September 18, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
September 18, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
September 18, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care
September 16, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy
September 14, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes
September 10, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Announces Launch of Offering of Senior Notes
September 07, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline
September 04, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential
September 02, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September
September 01, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.
August 31, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
August 28, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
August 19, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy
August 11, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1